Semaglutide Has Lasting Benefit for Weight Loss
By Elana Gotkine HealthDay Reporter
TUESDAY, May 21, 2024 -- Semaglutide has a long-term beneficial impact on weight, as well as cardiovascular benefits, regardless of weight loss, according to two studies presented at the annual meeting of the European Congress on Obesity, hosted by the European Association for the Study of Obesity from May 12 to 15 in Venice, Italy. One of the studies was also published online May 13 in Nature Medicine.
Donna H. Ryan, M.D., from Pennington Biomedical Research Center in Baton Rouge, Louisiana, and colleagues conducted a prespecified analysis involving 17,604 adults to examine the effects of semaglutide on weight and anthropometric outcomes, safety, and tolerability by baseline body mass index. The researchers found that weight loss continued over 65 weeks among patients treated with semaglutide and was sustained for up to four years. Compared with placebo, semaglutide was significantly associated with mean reduction in weight, waist circumference, and waist-to-height ratio at 208 weeks.
John Deanfield, from University College London, and colleagues reported a prespecified analysis of the relationship between weight measures and cardiovascular outcomes among 17,604 adults aged 45 years and older with body mass index ≥27 kg/m2. Participants were randomly assigned to semaglutide or placebo for a mean of 40 months. The researchers found that compared with placebo, semaglutide reduced the risk for major adverse cardiovascular events (MACE), with no difference in the magnitude of benefit of semaglutide across baseline weight or anthropometric subgroups. The decline in MACE rates with semaglutide versus placebo was comparable for those who lost ≥5 percent, lost <5 percent, or gained weight.
"Our findings show that the magnitude of this treatment effect with semaglutide is independent of the amount of weight lost, suggesting that the drug has other actions which lower cardiovascular risk beyond reducing unhealthy body fat," Deanfield said in a statement.
Several authors from the Ryan study disclosed ties to the biopharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
![](/img/logo/vendor/healthday-logo.png)
© 2024 HealthDay. All rights reserved.
Posted May 2024
Read this next
Small Differences in Weight Change With First-Line Antidepressants
MONDAY, July 1, 2024 -- For eight first-line antidepressants, small differences are seen in mean weight change, with the least weight gain with bupropion, according to a study...
Bariatric Surgery Tied to Lower Risk of MACE, Death in Obesity, Sleep Apnea
FRIDAY, June 28, 2024 -- Metabolic surgery is associated with significantly lower risk of major adverse cardiovascular events (MACE) compared with nonsurgical management among...
Exercise + GLP-1 RA Effective for Weight Loss While Preserving BMD
THURSDAY, June 27, 2024 -- For adults with obesity, without diabetes, combining exercise with the glucagon-like peptide-1 receptor agonist (GLP-1 RA), liraglutide, is effective...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.